AstraZeneca aims for summer start for COVID-19 antibody trial
AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S.
As part of the Defense Advanced Research Projects Agency (DARPA's) Pandemic Preparedness Platform program, AstraZeneca has developed competencies to discover antibodies against emerging viral threats. AstraZeneca first disclosed that it is developing coronavirus-neutralizing antibodies, along with putting more than 50 experts in fields such as virology ...
